Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 42 recruiting now early-phase tilt #67 of 28,707 conditions

Parkinson's Disease: early-phase trial registry

42 of 161 indexed Parkinson's Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #67 of 28,707 conditions by registered trial count.

161 US clinical trials · 42 currently recruiting · #67 of 28,707 conditions by registered trial count

Parkinson's Disease: 161 US clinical trials tracked, 42 recruiting.

Parkinson's Disease is the subject of 161 registered US clinical trials on ClinicalTrials.gov, 42 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 55 in Phase 1-2 (earlier-stage). The most active sponsor is VA Office of Research and Development, running 16 of these trials.

Enrollment posture brief

Registry condition parkinsons-disease

OPEN 42 | RECR 26% | LATE 21 | EARLY 55 | RANK #67 | SPON 16

Nearest open-share peer: Barrett's Esophagus (26% recruiting · 23 trials)

Epilepsy47.6%Gastric Cancer45.3%Neoplasms31.3%Parkinson's Disease (this)26%Bipolar Disorder22.7%
Open-enrollment share among volume-matched conditions near Parkinson's Disease

Parkinson's Disease lists 42 open slots (26% of 161 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Parkinson's Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Parkinson's Disease is recruiting below its size-band peers.

    42 of 161 indexed trials (26.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Parkinson's Disease trials is spread across many organizations.

    VA Office of Research and Development accounts for 16 of 161 trials (9.9%). 99 distinct sponsors appear on at least one study for this condition label.

  3. Most Parkinson's Disease trials plan to enrol fewer than 100 people.

    Median target enrolment is 51 among the 159 trials that report a genuine target (sentinel values excluded). 100 of those (62.9%) plan for fewer than 100 participants.

  4. Parkinson's Disease research is mostly interventional.

    114 interventional and 47 observational studies make up this index (70.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 124Phase 231Phase 311Phase 410

Open and recent trials

161 total, page 4 of 4

COMPLETED Phase 3 10 participants

Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa

University of Chicago

NCT00203957

COMPLETED 10 participants

Prospective Evaluation of Forceplate Measured Levodopa-Induced Dyskinesia

Oregon Health and Science University

NCT00912977

COMPLETED NA 10 participants

Transcranial Direct Current Stimulation (tDCS) and Parkinson's Disease

University of Maryland, Baltimore

NCT01100762

COMPLETED NA 9 participants

Effect of Exercise in Parkinsonism

VA Office of Research and Development

NCT02598973

COMPLETED NA 7 participants

Pilot Study for Automated Deep Brain Stimulation Programming

Great Lakes NeuroTechnologies

NCT02046863

COMPLETED 7 participants

Relationship Between Symptoms, Retinal Morphology, and the Nigrostriatal Dopamine System in Parkinson's Disease

Thomas Jefferson University

NCT02443779

COMPLETED Phase 4 6 participants

Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus

University of Wisconsin, Madison

NCT01721460

COMPLETED Early Phase 1 4 participants

Subthalamic Deep Brain Stimulation (DBS) in Parkinson's Disease

University of Florida

NCT02012647

COMPLETED Phase 1 1 participants

State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With Deep Brain Stimulation (DBS)

University of Minnesota

NCT02709148

COMPLETED Phase 2

Parkinson's Disease Treatment With Coenzyme Q10

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00004731

COMPLETED Phase 3

A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease

UCB Pharma

NCT00139867

← Previous Page 4 of 4

Phase Distribution

PhaseTrial count
Phase 1 24
Phase 2 31
Phase 3 11
Phase 4 10

Named interventions

Most-linked intervention names on Parkinson's Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
19 trials
Rasagiline Drug
6 trials
Placebo Other
4 trials
Health education Behavioral
3 trials
Deep Brain Stimulation Device
3 trials
rasagiline mesylate Drug
2 trials
Istradefylline (KW-6002) Drug
2 trials
IPX066 Drug
2 trials

US sites by state

Facility locations filed on Parkinson's Disease trials. A trial with sites in several states counts in each.

California 44 trials
Florida 36 trials
New York 26 trials
Illinois 25 trials
Georgia 22 trials
Colorado 22 trials
Massachusetts 21 trials
Arizona 20 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Parkinson's Disease page

161 registered trials, 42 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Parkinson's Disease condition card totals 161 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.